VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (âOptimiâ or the âCompanyâ), is pleased to announce that Mr. Bryan Safarik, Mr. Jacob Safarik, Mr. Jon Schintler, Mr. Dane Stevens, and Mr. JJ Wilson have been re-elected to the Board of Directors following the Companyâs Annual General Meeting held January 9, 2023. The Company would like to thank departing director Mr. Michael Stier for his service and wishes him well in his future endeavours. Optimi shareholders also re-appointed Smythe LLP as auditor and re-approved the Companyâs Equity Incentive Plan.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Companyâs goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimiâs products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.
FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:
Michael Kydd
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
FORWARD-LOOKING STATEMENTS
This news release contains forwardâlooking statements and forwardâlooking information within the meaning of Canadian securities legislation (collectively, âforwardâlooking statementsâ) that relate to Optimiâs current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as âwill likely result,â âare expected to,â âexpects,â âwill continue,â âis anticipated,â âanticipates,â âbelieves,â âestimated,â âintends,â âplans,â âforecast,â âprojection,â âstrategy,â âobjective,â and âoutlookâ) are not historical facts and may be forwardâlooking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forwardâlooking statements. No assurance can be given that these expectations will prove to be correct and such forwardâlooking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forwardâlooking statements pertaining to activities proposed to be conducted under the Companyâs approved Health Canada dealerâs licence and associated business related to Psilocybin, Psilocin, other psychedelic substances, some being synthetically formulated, and Optimiâs plans, focus and objectives.
Forwardâlooking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimiâs control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forwardâlooking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVIDâ19 pandemic and other factors set forth under âForwardâLooking Statementsâ and âRisk Factorsâ in the Companyâs Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimiâs profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forwardâlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forwardâlooking statement.
Any forwardâlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.